Loading stock data…
$2.27+0.01 (+0.22%)
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Perspective Therapeutics, Inc. in the Healthcare sector is trading at $2.27 with a market capitalization of $321M. Wall Street consensus targets $12.29 (14 analysts), implying a +440.0% move over the next 12 months. The stock is currently near its 52-week low of $1.96, remaining 36.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.26M↓ | -$28.28M↑ | -$39.83M↓ | -$27.86M↓ | -$24.04M |
| Net Income | -$26.79M↓ | -$26.19M↑ | -$37.49M↓ | -$25.97M↓ | -$21.48M |
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that ...